22 results on '"Solomon, Alina"'
Search Results
2. Life-course stress, cognition, and diurnal cortisol in memory clinic patients without dementia
- Author
-
Holleman, Jasper, Kåreholt, Ingemar, Aspö, Malin, Hagman, Göran, Udeh-Momoh, Chinedu T., Kivipelto, Miia, Solomon, Alina, and Sindi, Shireen
- Published
- 2024
- Full Text
- View/download PDF
3. Cognitive reserve, cortisol, and Alzheimer's disease biomarkers: A memory clinic study
- Author
-
Yerramalla, Manasa Shanta, primary, Darin‐Mattsson, Alexander, additional, Udeh‐Momoh, Chinedu T, additional, Holleman, Jasper, additional, Kåreholt, Ingemar, additional, Aspö, Malin, additional, Hagman, Göran, additional, Kivipelto, Miia, additional, Solomon, Alina, additional, Marseglia, Anna, additional, and Sindi, Shireen, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Diverging medical and legal perceptions of the need for legal guardianship in people with dementia: A qualitative study
- Author
-
Näkki, Kaisa, primary, Mäki‐Petäjä‐Leinonen, Anna, additional, Ervasti, Kaijus, additional, Halkoaho, Arja, additional, Nurmi, Sanna‐Maria, additional, Solomon, Alina, additional, Suhonen, Noora‐Maria, additional, Portaankorva, Anne M., additional, Krüger, Johanna, additional, and Solje, Eino, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: Findings from the Co-STAR study.
- Author
-
Daniilidou, Makrina, Holleman, Jasper, Hagman, Göran, Kåreholt, Ingemar, Aspö, Malin, Brinkmalm, Ann, Zetterberg, Henrik, Blennow, Kaj, Solomon, Alina, Kivipelto, Miia, Sindi, Shireen, and Matton, Anna
- Published
- 2024
- Full Text
- View/download PDF
6. Nutrition guidance within a multimodal intervention improves diet quality in prodromal Alzheimer's disease: Multimodal Preventive Trial for Alzheimer's Disease (MIND-ADmini).
- Author
-
Levak, Nicholas, Lehtisalo, Jenni, Thunborg, Charlotta, Westman, Eric, Andersen, Pia, Andrieu, Sandrine, Broersen, Laus M., Coley, Nicola, Hartmann, Tobias, Irving, Gerd Faxén, Mangialasche, Francesca, Ngandu, Tiia, Pantel, Johannes, Rosenberg, Anna, Sindi, Shireen, Soininen, Hilkka, Solomon, Alina, Wang, Rui, and Kivipelto, Miia
- Subjects
ALZHEIMER'S disease ,NUTRIENT density ,NUTRITIONAL status ,ALZHEIMER'S patients ,FOOD consumption - Abstract
Background: Multimodal lifestyle interventions can benefit overall health, including cognition, in populations at-risk for dementia. However, little is known about the effect of lifestyle interventions in patients with prodromal Alzheimer's disease (AD). Even less is known about dietary intake and adherence to dietary recommendations within this population making it difficult to design tailored interventions for them. Method: A 6-month MIND-AD
mini pilot randomized controlled trial (RCT) was conducted among 93 participants with prodromal AD in Sweden, Finland, Germany, and France. Three arms were included in the RCT: 1) multimodal lifestyle intervention (nutritional guidance, exercise, cognitive training, vascular/metabolic risk management, and social stimulation); 2) multimodal lifestyle intervention + medical food product; and 3) regular health advice (control group). Adherence to dietary advice was assessed with a brief food intake questionnaire by using the Healthy Diet Index (HDI) and Mediterranean Diet Adherence Screener (MEDAS). The intake of macro- and micronutrients were analyzed on a subsample using 3-day food records. Results: The dietary quality in the intervention groups, pooled together, improved compared to that of the control group at the end of the study, as measured with by HDI (p = 0.026) and MEDAS (p = 0.008). The lifestyle-only group improved significantly more in MEDAS (p = 0.046) and almost significantly in HDI (p = 0.052) compared to the control group, while the lifestyle + medical food group improved in both HDI (p = 0.042) and MEDAS (p = 0.007) during the study. There were no changes in macro- or micronutrient intake for the intervention groups at follow-up; however, the intakes in the control group declined in several vitamins and minerals when adjusted for energy intake. Conclusion: These results suggest that dietary intervention as part of multimodal lifestyle interventions is feasible and results in improved dietary quality in a population with prodromal AD. Nutrient intakes remained unchanged in the intervention groups while the control group showed a decreasing nutrient density. Trial registration: ClinicalTrials.gov NCT03249688, 2017–07-08. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
7. Association of tooth location, occlusal support and chewing ability with cognitive decline and incident dementia
- Author
-
Asher, Sam, primary, Suominen, Anna Liisa, additional, Stephen, Ruth, additional, Ngandu, Tiia, additional, Koskinen, Seppo, additional, and Solomon, Alina, additional
- Published
- 2024
- Full Text
- View/download PDF
8. The Australian National University Alzheimer's Disease Risk Index (ANU‐ADRI) score as a predictor for cognitive decline and potential surrogate outcome in the FINGER lifestyle randomized controlled trial
- Author
-
Hall, Anette, primary, Barbera, Mariagnese, additional, Lehtisalo, Jenni, additional, Antikainen, Riitta, additional, Huque, Hamidul, additional, Laatikainen, Tiina, additional, Ngandu, Tiia, additional, Soininen, Hilkka, additional, Stephen, Ruth, additional, Strandberg, Timo, additional, Kivipelto, Miia, additional, Anstey, Kaarin J., additional, and Solomon, Alina, additional
- Published
- 2024
- Full Text
- View/download PDF
9. Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial.
- Author
-
Saadmaan, Gazi, Dalmasso, Maria Carolina, Ramirez, Alfredo, Hiltunen, Mikko, Kemppainen, Nina, Lehtisalo, Jenni, Mangialasche, Francesca, Ngandu, Tiia, Rinne, Juha, Soininen, Hilkka, Stephen, Ruth, Kivipelto, Miia, and Solomon, Alina
- Abstract
INTRODUCTION: We assessed a genetic risk score for Alzheimer's disease (AD‐GRS) and apolipoprotein E (APOE4) in an exploratory neuroimaging substudy of the FINGER trial. METHODS: 1260 at‐risk older individuals without dementia were randomized to multidomain lifestyle intervention or health advice. N = 126 participants underwent magnetic resonance imaging (MRI), and N = 47 positron emission tomography (PET) scans (Pittsburgh Compund B [PiB], Fluorodeoxyglucose) at baseline; N = 107 and N = 38 had repeated 2‐year scans. RESULTS: The APOE4 allele, but not AD‐GRS, was associated with baseline lower hippocampus volume (β = −0.27, p = 0.001), greater amyloid deposition (β = 0.48, p = 0.001), 2‐year decline in hippocampus (β = −0.27, p = 0.01), total gray matter volume (β = −0.25, p = 0.01), and cortical thickness (β = −0.28, p = 0.003). In analyses stratified by AD‐GRS (below vs above median), the PiB composite score increased less in intervention versus control in the higher AD‐GRS group (β = −0.60, p = 0.03). DISCUSSION: AD‐GRS and APOE4 may have different impacts on potential intervention effects on amyloid, that is, less accumulation in the higher‐risk group (AD‐GRS) versus lower‐risk group (APOE). Highlights: First study of neuroimaging and AD genetics in a multidomain lifestyle intervention.Possible intervention effect on brain amyloid deposition may rely on genetic risk.AD‐GRS and APOE4 allele may have different impacts on amyloid during intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Development of a Cognitive Training Support Programme for prevention of dementia and cognitive decline in at-risk older adults.
- Author
-
de Jager Loots, Celeste A., Price, Geraint, Barbera, Mariagnese, Neely, Anna Stigsdotter, Gavelin, Hanna M., Lehtisalo, Jenni, Ngandu, Tiia, Solomon, Alina, Mangialasche, Francesca, and Kivipelto, Miia
- Published
- 2024
- Full Text
- View/download PDF
11. Sleep disturbances and change in multiple cognitive domains among older adults: a multicenter study of five Nordic cohorts.
- Author
-
Overton, Marieclaire, Skoog, Johan, Laukka, Erika J, Bodin, Timothy Hadarsson, Mattsson, Alexander Darin, Sjöberg, Linnea, Hofer, Scott M, Johansson, Lena, Kulmala, Jenni, Kivipelto, Miia, Solomon, Alina, Skoog, Ingmar, Kåreholt, Ingemar, and Sindi, Shireen
- Published
- 2024
- Full Text
- View/download PDF
12. Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals.
- Author
-
Moradi, Elaheh, Prakash, Mithilesh, Hall, Anette, Solomon, Alina, Strange, Bryan, and Tohka, Jussi
- Subjects
MACHINE learning ,AMYLOID ,POSITRON emission tomography ,MILD cognitive impairment ,ALZHEIMER'S disease - Abstract
Background: The pathophysiology of Alzheimer's disease (AD) involves β -amyloid (A β ) accumulation. Early identification of individuals with abnormal β -amyloid levels is crucial, but A β quantification with positron emission tomography (PET) and cerebrospinal fluid (CSF) is invasive and expensive. Methods: We propose a machine learning framework using standard non-invasive (MRI, demographics, APOE, neuropsychology) measures to predict future A β -positivity in A β -negative individuals. We separately study A β -positivity defined by PET and CSF. Results: Cross-validated AUC for 4-year A β conversion prediction was 0.78 for the CSF-based and 0.68 for the PET-based A β definitions. Although not trained for the clinical status-change prediction, the CSF-based model excelled in predicting future mild cognitive impairment (MCI)/dementia conversion in cognitively normal/MCI individuals (AUCs, respectively, 0.76 and 0.89 with a separate dataset). Conclusion: Standard measures have potential in detecting future A β -positivity and assessing conversion risk, even in cognitively normal individuals. The CSF-based definition led to better predictions than the PET-based definition. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER).
- Author
-
Baker, Laura D., Snyder, Heather M., Espeland, Mark A., Whitmer, Rachel A., Kivipelto, Miia, Woolard, Nancy, Katula, Jeffrey, Papp, Kathryn V., Ventrelle, Jennifer, Graef, Sarah, Hill, Marcus A., Rushing, Scott, Spell, Julia, Lovato, Laura, Felton, Deborah, Williams, Benjamin J., Ghadimi Nouran, Mina, Raman, Rema, Ngandu, Tiia, and Solomon, Alina
- Abstract
INTRODUCTION: The U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER) is conducted to confirm and expand the results of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) in Americans. METHODS: U.S. POINTER was planned as a 2‐year randomized controlled trial of two lifestyle interventions in 2000 older adults at risk for dementia due to well‐established factors. The primary outcome is a global cognition composite that permits harmonization with FINGER. RESULTS: U.S. POINTER is centrally coordinated and conducted at five clinical sites (ClinicalTrials.gov: NCT03688126). Outcomes assessments are completed at baseline and every 6 months. Both interventions focus on exercise, diet, cognitive/social stimulation, and cardiovascular health, but differ in intensity and accountability. The study partners with a worldwide network of similar trials for harmonization of methods and data sharing. DISCUSSION: U.S. POINTER is testing a potentially sustainable intervention to support brain health and Alzheimer's prevention for Americans. Impact is strengthened by the targeted participant diversity and expanded scientific scope through ancillary studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol.
- Author
-
Barbera, Mariagnese, Lehtisalo, Jenni, Perera, Dinithi, Aspö, Malin, Cross, Mary, De Jager Loots, Celeste A., Falaschetti, Emanuela, Friel, Naomi, Luchsinger, José A., Gavelin, Hanna Malmberg, Peltonen, Markku, Price, Geraint, Neely, Anna Stigsdotter, Thunborg, Charlotta, Tuomilehto, Jaakko, Mangialasche, Francesca, Middleton, Lefkos, Ngandu, Tiia, Solomon, Alina, and Kivipelto, Miia
- Subjects
COGNITION disorders ,METFORMIN ,ALZHEIMER'S disease ,TYPE 2 diabetes ,HEALTH behavior ,PEOPLE with disabilities ,DISEASE risk factors ,SELF-monitoring (Psychology) - Abstract
Background: Combining multimodal lifestyle interventions and disease-modifying drugs (novel or repurposed) could provide novel precision approaches to prevent cognitive impairment. Metformin is a promising candidate in view of the well-established link between type 2 diabetes (T2D) and Alzheimer's Disease and emerging evidence of its potential neuro-protective effects (e.g. vascular, metabolic, anti-senescence). MET-FINGER aims to test a FINGER 2.0 multimodal intervention, combining an updated FINGER multidomain lifestyle intervention with metformin, where appropriate, in an APOE ε4-enriched population of older adults (60–79 years) at increased risk of dementia. Methods: MET-FINGER is an international randomised, controlled, parallel-group, phase-IIb proof-of-concept clinical trial, where metformin is included through a trial-within-trial design. 600 participants will be recruited at three sites (UK, Finland, Sweden). Participants at increased risk of dementia based on vascular risk factors and cognitive screening, will be first randomised to the FINGER 2.0 intervention (lifestyle + metformin if eligible; active arm) or to receive regular health advice (control arm). Participants allocated to the FINGER 2.0 intervention group at risk indicators of T2D will be additionally randomised to receive metformin (2000 mg/day or 1000 mg/day) or placebo. The study duration is 2 years. The changes in global cognition (primary outcome, using a Neuropsychological Test Battery), memory, executive function, and processing speed cognitive domains; functional status; lifestyle, vascular, metabolic, and other dementia-related risk factors (secondary outcomes), will be compared between the FINGER 2.0 intervention and the control arm. The feasibility, potential interaction (between-groups differences in healthy lifestyle changes), and disease-modifying effects of the lifestyle-metformin combination will be exploratory outcomes. The lifestyle intervention is adapted from the original FINGER trial (diet, physical activity, cognitive training, monitoring of cardiovascular/metabolic risk factors, social interaction) to be consistently delivered in three countries. Metformin is administered as Glucophage®XR/SR 500, (500 mg oral tablets). The metformin/placebo treatment will be double blinded. Conclusion: MET-FINGER is the first trial combining a multimodal lifestyle intervention with a putative repurposed disease-modifying drug for cognitive impairment prevention. Although preliminary, its findings will provide crucial information for innovative precision prevention strategies and form the basis for a larger phase-III trial design and future research in this field. Trial registration: ClinicalTrials.gov (NCT05109169). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. 0219 Sleep Disturbances, Cortisol, and Neuroimaging Correlates Among Memory Clinic Patients
- Author
-
Sørensen, Charlotte, Kåreholt, Ingemar, Kalpouzos, Grégoria, Udeh-Momoh, Chinedu T, Holleman, Jasper, Aspö, Malin, Hagman, Göran, Spulber, Gabriela, Kivipelto, Miia, Solomon, Alina, and Sindi, Shireen
- Published
- 2024
- Full Text
- View/download PDF
16. Brain amyloid load, subjective memory complaints, and cognitive trajectories in older individuals at risk for dementia.
- Author
-
Saadmaan, Gazi, Hall, Anette, Ngandu, Tiia, Kemppainen, Nina, Mangialasche, Francesca, Wittenberg, Gayle M., Matton, Anna, Rinne, Juha O., Kivipelto, Miia, and Solomon, Alina
- Subjects
- *
POSITRON emission tomography , *PROSPECTIVE memory , *EXECUTIVE function , *OLDER people , *DISEASE risk factors - Abstract
Background and Purpose Methods Results Conclusions This study evaluated associations of brain amyloid with 2‐year objective and subjective cognitive measures in a trial‐ready older general population at risk for dementia.Forty‐eight participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability underwent 11C‐Pittsburgh compound B (PiB) positron emission tomography (PET) scans and assessment of cognition (modified Neuropsychological Test Battery [NTB]) and subjective memory complaints (Prospective and Retrospective Memory Questionnaire).Mean age was 71.4 ± 5.06 years, and 20 participants (42%) had positive baseline PiB‐PET scans. Amyloid positivity was associated with lower NTB executive function at baseline and less favorable 2‐year NTB total score and memory trajectories, but not with other objective or subjective cognitive measures. Overall, there was little cognitive decline during 2 years.Amyloid accumulation may affect objective but not necessarily subjective cognition from a very early at‐risk stage, although substantial decline likely requires >2 years to occur. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Nutrition guidance within a multimodal intervention improves diet quality in prodromal Alzheimer's disease: Multimodal Preventive Trial for Alzheimer's Disease (MIND-ADmini).
- Author
-
Levak, Nicholas, Lehtisalo, Jenni, Thunborg, Charlotta, Westman, Eric, Andersen, Pia, Andrieu, Sandrine, Broersen, Laus M., Coley, Nicola, Hartmann, Tobias, Irving, Gerd Faxén, Mangialasche, Francesca, Ngandu, Tiia, Pantel, Johannes, Rosenberg, Anna, Sindi, Shireen, Soininen, Hilkka, Solomon, Alina, Wang, Rui, and Kivipelto, Miia
- Subjects
- *
ALZHEIMER'S disease , *NUTRIENT density , *NUTRITIONAL status , *ALZHEIMER'S patients , *FOOD consumption - Abstract
Background: Multimodal lifestyle interventions can benefit overall health, including cognition, in populations at-risk for dementia. However, little is known about the effect of lifestyle interventions in patients with prodromal Alzheimer's disease (AD). Even less is known about dietary intake and adherence to dietary recommendations within this population making it difficult to design tailored interventions for them. Method: A 6-month MIND-ADmini pilot randomized controlled trial (RCT) was conducted among 93 participants with prodromal AD in Sweden, Finland, Germany, and France. Three arms were included in the RCT: 1) multimodal lifestyle intervention (nutritional guidance, exercise, cognitive training, vascular/metabolic risk management, and social stimulation); 2) multimodal lifestyle intervention + medical food product; and 3) regular health advice (control group). Adherence to dietary advice was assessed with a brief food intake questionnaire by using the Healthy Diet Index (HDI) and Mediterranean Diet Adherence Screener (MEDAS). The intake of macro- and micronutrients were analyzed on a subsample using 3-day food records. Results: The dietary quality in the intervention groups, pooled together, improved compared to that of the control group at the end of the study, as measured with by HDI (p = 0.026) and MEDAS (p = 0.008). The lifestyle-only group improved significantly more in MEDAS (p = 0.046) and almost significantly in HDI (p = 0.052) compared to the control group, while the lifestyle + medical food group improved in both HDI (p = 0.042) and MEDAS (p = 0.007) during the study. There were no changes in macro- or micronutrient intake for the intervention groups at follow-up; however, the intakes in the control group declined in several vitamins and minerals when adjusted for energy intake. Conclusion: These results suggest that dietary intervention as part of multimodal lifestyle interventions is feasible and results in improved dietary quality in a population with prodromal AD. Nutrient intakes remained unchanged in the intervention groups while the control group showed a decreasing nutrient density. Trial registration: ClinicalTrials.gov NCT03249688, 2017–07-08. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Nutrition guidance within a multimodal intervention improves diet quality in prodromal Alzheimer's disease: Multimodal Preventive Trial for Alzheimer's Disease (MIND-AD mini ).
- Author
-
Levak N, Lehtisalo J, Thunborg C, Westman E, Andersen P, Andrieu S, Broersen LM, Coley N, Hartmann T, Irving GF, Mangialasche F, Ngandu T, Pantel J, Rosenberg A, Sindi S, Soininen H, Solomon A, Wang R, and Kivipelto M
- Subjects
- Humans, Male, Female, Aged, Pilot Projects, Life Style, Diet, Mediterranean, Exercise, Diet methods, Combined Modality Therapy, Middle Aged, Diet, Healthy methods, Alzheimer Disease diet therapy, Alzheimer Disease prevention & control, Prodromal Symptoms
- Abstract
Background: Multimodal lifestyle interventions can benefit overall health, including cognition, in populations at-risk for dementia. However, little is known about the effect of lifestyle interventions in patients with prodromal Alzheimer's disease (AD). Even less is known about dietary intake and adherence to dietary recommendations within this population making it difficult to design tailored interventions for them., Method: A 6-month MIND-AD
mini pilot randomized controlled trial (RCT) was conducted among 93 participants with prodromal AD in Sweden, Finland, Germany, and France. Three arms were included in the RCT: 1) multimodal lifestyle intervention (nutritional guidance, exercise, cognitive training, vascular/metabolic risk management, and social stimulation); 2) multimodal lifestyle intervention + medical food product; and 3) regular health advice (control group). Adherence to dietary advice was assessed with a brief food intake questionnaire by using the Healthy Diet Index (HDI) and Mediterranean Diet Adherence Screener (MEDAS). The intake of macro- and micronutrients were analyzed on a subsample using 3-day food records., Results: The dietary quality in the intervention groups, pooled together, improved compared to that of the control group at the end of the study, as measured with by HDI (p = 0.026) and MEDAS (p = 0.008). The lifestyle-only group improved significantly more in MEDAS (p = 0.046) and almost significantly in HDI (p = 0.052) compared to the control group, while the lifestyle + medical food group improved in both HDI (p = 0.042) and MEDAS (p = 0.007) during the study. There were no changes in macro- or micronutrient intake for the intervention groups at follow-up; however, the intakes in the control group declined in several vitamins and minerals when adjusted for energy intake., Conclusion: These results suggest that dietary intervention as part of multimodal lifestyle interventions is feasible and results in improved dietary quality in a population with prodromal AD. Nutrient intakes remained unchanged in the intervention groups while the control group showed a decreasing nutrient density., Trial Registration: ClinicalTrials.gov NCT03249688, 2017-07-08., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
19. Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial.
- Author
-
Saadmaan G, Dalmasso MC, Ramirez A, Hiltunen M, Kemppainen N, Lehtisalo J, Mangialasche F, Ngandu T, Rinne J, Soininen H, Stephen R, Kivipelto M, and Solomon A
- Subjects
- Humans, Male, Female, Aged, Brain diagnostic imaging, Brain pathology, Genetic Predisposition to Disease, Middle Aged, Risk Factors, Genetic Risk Score, Alzheimer Disease genetics, Alzheimer Disease diagnostic imaging, Positron-Emission Tomography, Neuroimaging, Magnetic Resonance Imaging, Apolipoprotein E4 genetics, Life Style
- Abstract
Introduction: We assessed a genetic risk score for Alzheimer's disease (AD-GRS) and apolipoprotein E (APOE4) in an exploratory neuroimaging substudy of the FINGER trial., Methods: 1260 at-risk older individuals without dementia were randomized to multidomain lifestyle intervention or health advice. N = 126 participants underwent magnetic resonance imaging (MRI), and N = 47 positron emission tomography (PET) scans (Pittsburgh Compund B [PiB], Fluorodeoxyglucose) at baseline; N = 107 and N = 38 had repeated 2-year scans., Results: The APOE4 allele, but not AD-GRS, was associated with baseline lower hippocampus volume (β = -0.27, p = 0.001), greater amyloid deposition (β = 0.48, p = 0.001), 2-year decline in hippocampus (β = -0.27, p = 0.01), total gray matter volume (β = -0.25, p = 0.01), and cortical thickness (β = -0.28, p = 0.003). In analyses stratified by AD-GRS (below vs above median), the PiB composite score increased less in intervention versus control in the higher AD-GRS group (β = -0.60, p = 0.03)., Discussion: AD-GRS and APOE4 may have different impacts on potential intervention effects on amyloid, that is, less accumulation in the higher-risk group (AD-GRS) versus lower-risk group (APOE)., Highlights: First study of neuroimaging and AD genetics in a multidomain lifestyle intervention. Possible intervention effect on brain amyloid deposition may rely on genetic risk. AD-GRS and APOE4 allele may have different impacts on amyloid during intervention., (© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
- Published
- 2024
- Full Text
- View/download PDF
20. Integrating a multimodal lifestyle intervention with medical food in prodromal Alzheimer's disease: the MIND-AD mini randomized controlled trial.
- Author
-
Thunborg C, Wang R, Rosenberg A, Sindi S, Andersen P, Andrieu S, Broersen LM, Coley N, Couderc C, Duval CZ, Faxen-Irving G, Hagman G, Hallikainen M, Håkansson K, Kekkonen E, Lehtisalo J, Levak N, Mangialasche F, Pantel J, Rydström A, Stigsdotter-Neely A, Wimo A, Ngandu T, Soininen H, Hartmann T, Solomon A, and Kivipelto M
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Aged, 80 and over, Prodromal Symptoms, Combined Modality Therapy methods, Exercise physiology, Cognitive Dysfunction therapy, Cognitive Dysfunction prevention & control, Alzheimer Disease therapy, Alzheimer Disease psychology, Life Style
- Abstract
Background: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) showed cognitive benefits from a multidomain lifestyle intervention in at-risk older people. The LipiDiDiet trial highlighted benefits of medical food in prodromal Alzheimer's disease (AD). However, the feasibility and impact of multimodal interventions combining lifestyle with medical food in prodromal AD is unclear., Methods: MIND-AD
mini was a 6-month multinational (Sweden, Finland, Germany, France) proof-of-concept randomized controlled trial (RCT). Participants were 60-85 years old, had prodromal AD (International Working Group-1 criteria), and vascular/lifestyle risk factors. The parallel-group RCT had three arms: multimodal lifestyle intervention (nutritional guidance, exercise, cognitive training, vascular/metabolic risk management and social stimulation); multimodal lifestyle intervention + medical food (Fortasyn Connect); and regular health advice/care (control). Participants were randomized 1:1:1 (computer-generated allocation at each site). Outcome evaluators were blinded to randomization. Primary outcome was feasibility of the multimodal intervention, evaluated by recruitment rate during a 6-month recruitment phase, overall adherence in each intervention arm, and 6-month retention rate. Successful adherence was pre-specified as attending ≥ 40% of sessions/domain in ≥ 2/4 domains (lifestyle intervention), and consuming ≥ 60% of the medical food (lifestyle intervention + medical food). The secondary outcomes included adherence/participation to each intervention component and overall adherence to healthy lifestyle changes, measured using a composite score for healthy lifestyle. Cognitive assessments were included as exploratory outcomes, e.g. Clinical Dementia Rating scale., Results: During September 2017-May 2019, 93 individuals were randomized (32 lifestyle intervention, 31 lifestyle + medical food, and 30 control group). Overall recruitment rate was 76.2% (64.8% during the first 6 months). Overall 6-month retention rate was 91.4% (lifestyle intervention 87.5%; lifestyle + medical food 90.3%; control 96.7%). Domain-specific adherence in the lifestyle intervention group was 71.9% to cognitive training, 78.1% exercise, 68.8% nutritional guidance, and 81.3% vascular risk management; and in the lifestyle + medical food group, 90.3% to cognitive training, 87.1% exercise, 80.7% nutritional guidance, 87.1% vascular risk management, and 87.1% medical food. Compared with control, both intervention arms showed healthy diet improvements (βLifestyle×Time = 1.11, P = 0.038; βLifestyle+medical food×Time = 1.43, P = 0.007); the lifestyle + medical food group also showed vascular risk reduction (P = 0.043) and less cognitive-functional decline (P < 0.05, exploratory analysis). There were 5 serious adverse events (control group: 1; lifestyle intervention: 3; lifestyle + medical food: 1) unrelated to interventions., Conclusions: The multidomain lifestyle intervention, alone or combined with medical food, had good feasibility and adherence in prodromal AD. Longer-term cognitive and other health benefits should be further investigated in a larger-scale trial., Trial Registration: ClinicalTrials.gov NCT03249688., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
21. [The end of dialysis: the weariness to carry on].
- Author
-
Maccaferri GE, Banava E, Duc L, Gamondi C, Fekih Ghorbel Y, and Solomon AR
- Subjects
- Humans, Quality of Life, Palliative Care, Renal Dialysis, Mental Disorders psychology
- Abstract
Voluntary cessation of hemodialysis is a common cause of death in dialysis patients, often occurring related to an alteration in their quality of life. At the same time, psychiatric disorders such as depression or anxiety are common and often underestimated among these patients, that accentuate the suffering and complicate compliance with dialysis. In this paper some psychopathological conditions will be addressed, as well as the question of the patient's ambivalence towards dialysis and the clinical and ethical dilemma of caregivers: respect the patient's choice to stop treatment or keep them alive at all costs? A multidisciplinary approach, including palliative care, is essential to support the reflection and make balanced decisions while respecting patient autonomy., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
- Published
- 2024
- Full Text
- View/download PDF
22. Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER).
- Author
-
Baker LD, Snyder HM, Espeland MA, Whitmer RA, Kivipelto M, Woolard N, Katula J, Papp KV, Ventrelle J, Graef S, Hill MA, Rushing S, Spell J, Lovato L, Felton D, Williams BJ, Ghadimi Nouran M, Raman R, Ngandu T, Solomon A, Wilmoth S, Cleveland ML, Williamson JD, Lambert KL, Tomaszewski Farias S, Day CE, Tangney CC, Gitelman DR, Matongo O, Reynolds T, Pavlik VN, Yu MM, Alexander AS, Elbein R, McDonald AM, Salloway S, Wing RR, Antkowiak S, Morris MC, and Carrillo MC
- Subjects
- Humans, Aged, Life Style, Cognition, Exercise, Brain, Cognitive Dysfunction psychology
- Abstract
Introduction: The U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER) is conducted to confirm and expand the results of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) in Americans., Methods: U.S. POINTER was planned as a 2-year randomized controlled trial of two lifestyle interventions in 2000 older adults at risk for dementia due to well-established factors. The primary outcome is a global cognition composite that permits harmonization with FINGER., Results: U.S. POINTER is centrally coordinated and conducted at five clinical sites (ClinicalTrials.gov: NCT03688126). Outcomes assessments are completed at baseline and every 6 months. Both interventions focus on exercise, diet, cognitive/social stimulation, and cardiovascular health, but differ in intensity and accountability. The study partners with a worldwide network of similar trials for harmonization of methods and data sharing., Discussion: U.S. POINTER is testing a potentially sustainable intervention to support brain health and Alzheimer's prevention for Americans. Impact is strengthened by the targeted participant diversity and expanded scientific scope through ancillary studies., (© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.